Regeneron Pharmaceuticals, 245 Main St, Ste 2, Cambridge, MA 02142, US

Immuneering Corporation, based in Cambridge, MA, is a biopharmaceutical company dedicated to developing medicines with broad activity for large patient populations. Their lead clinical stage candidate, IMM-1-104, aims to achieve universal-RAS activity against tumors driven by mutations in RAS and beyond, selectively impacting cancer cells more than healthy cells through deep cyclic inhibition of the MAPK pathway. With a robust pipeline of novel drug programs, Immuneering is advancing their differentiated approach to drug development, which aims to deprive tumor cells of sustained proliferative signaling while sparing healthy cells. Their proprietary disease-agnostic platform, integrating bioinformatics and computational biology, allows them to leverage human biological data in innovative ways, providing counterintuitive insights unconstrained by conventional approaches or prevailing scientific views.Generated from the website

Root Capitol

Nanobiotix Corp

Biocon Biologics Inc

React Neuro